Your browser doesn't support javascript.
loading
Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study.
Feist, Eugen; Fatenejad, Saeed; Grishin, Sergey; Korneva, Elena; Luggen, Michael E; Nasonov, Evgeniy; Samsonov, Mikhail; Smolen, Josef S; Fleischmann, Roy M.
Afiliación
  • Feist E; Rheumatology and Clinical Immunology, HELIOS Fachklinik Vogelsang/Gommern, Vogelsang, Sachsen-Anhalt, Germany Eugen.Feist@helios-gesundheit.de.
  • Fatenejad S; SFC Medica LLC, Charlotte, North Carolina, USA.
  • Grishin S; Medical, R-Pharm Group, Moscow, Russian Federation.
  • Korneva E; Medical, CJSC R-Pharm, Moskow, Russian Federation.
  • Luggen ME; Department of Internal Medicine, Division of Rheumatology, Allergy, and Immunology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
  • Nasonov E; FSBSI V A Nasonov Research Institute of Rheumatology, Moscow, Russian Federation.
  • Samsonov M; Medical, CJSC R-Pharm, Moscow, Russian Federation.
  • Smolen JS; Division of Rheumatology, Department of Medicine, Medical University of Vienna, Wien, Austria.
  • Fleischmann RM; Medicine, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Ann Rheum Dis ; 81(12): 1661-1668, 2022 12.
Article en En | MEDLINE | ID: mdl-36109142

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Ann Rheum Dis Año: 2022 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos / Anticuerpos Monoclonales Tipo de estudio: Clinical_trials Límite: Humans Idioma: En Revista: Ann Rheum Dis Año: 2022 Tipo del documento: Article País de afiliación: Alemania